MTSR and PFE Related Headlines
Go Back- Pfizer completes $7 billion acquisition of obesity drugmaker Metsera
- Pfizer Completes Acquisition of Metsera
- Novo Nordisk shares rise on investor relief after it exits Metsera bid
- Pfizer amends merger deal with Metsera, raising value to $86.25 per share
- Novo CEO Says Bid For Metsera Is Higher Than Pfizer's Is Today
- Novo Nordisk Is Said To Sweeten Bid For Obesity Startup Metsera - Bloomberg
- Pfizer, Novo again raise Metsera bids in intensifying obesity drug battle
- Pfizer vows to continue Metsera legal fight after court denies restraining order
- Pfizer Preps Improved Offer In Metsera Bidding War - WSJ
- Pfizer Denied Temporary Block On Novo Nordisk’s Metsera Bid - Bloomberg
- Pfizer Drops Demand That Metsera Denounce Novo Bid: Metsera - Bloomberg
- FTC Says Novo-Metsera Bid Raises Merger Filing Concerns - Bloomberg
- Pfizer has removed conditions on sale of Arch Venture shares and Metsera public statements from its Metsera bid - Pfizer letter to court
- Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo
- Pfizer (PFE) CEO: our bid for Metsera has taken into consideration that prices of GLP-1 will probably start going down - Conference Call
- Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up
- Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies - FT
- Metsera declares Novo Nordisk's $10 billion bid superior to Pfizer offer
- Novo Nordisk says Metsera bid won't raise antitrust issues
- Metsera responds to Pfizer litigation amid competing acquisition bids
- Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit
- Pfizer files second lawsuit against Novo Nordisk over Metsera acquisition
- Metsera responds to Pfizer litigation, will address claims in court
- Pfizer sues Metsera directors and Novo Nordisk over merger breach
- Pfizer gets early FTC clearance for Metsera acquisition
- Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
- Pfizer mulls suing Metsera, Novo Nordisk over topping bid - Semafor
- Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ
- Novo Nodrisk stock dips on aggressive odder to buy Metsera, 'reckless' says Pfizer
- Pfizer calls Novo Nordisk's Metsera bid reckless and illegal
- Pfizer Addresses Proposal for Metsera
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Goldman on Pfizer (PFE) Post Metsera (MTSR) Deal: 'previously emphasized the importance of growing its footprint in internal medicines and primary care'
- BTIG on Pfizer (PFE) deal for Metsera (MTSR): 'representative of large pharma's strong interest in the obesity and metabolic disease platforms'
- Wolfe Research Comments on Path Forward for Pfizer (PFE) and Metsera (MTSR)
- Pfizer to acquire obesity drug developer Metsera for $4.9 billion
- Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
- Pfizer (PFE) Nears Potential $7.3 bln Takeover Of Metsera- FT
MTSR and PFE Related Press Releases
Go Back- Pfizer Completes Acquisition of Metsera
- Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
- Pfizer Addresses Proposal for Metsera
- Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
